Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The ...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...
Biodexa Strengthens Management TeamAppointment of Dr Gary A. Shangold as Chief Medical OfficerBiodexa Pharmaceuticals PLC ...
Biodexa Pharmaceuticals PLC has announced the appointment of Dr. Gary A. Shangold as Chief Medical Officer, effective immediately. CEO Stephen Stamp expressed enthusiasm for Dr. Shangold’s ...
北京时间2025年2月11日01时12分,Compugen医疗(CGEN.us)股票出现显著波动,股价下跌5.06%,报每股2.44美元,成交量达到39.73万股,换手率为0.44%,振幅为8.00%。
北京时间2025年02月11日03时19分,康乃德生物(CNTB.us)股票出现波动,股价快速下跌5.13%。截至发稿,该股报0.935美元/股,成交量1.7762万股, 换手率 0.03%,振幅3.04%。
Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...